Literature DB >> 28364253

Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect.

Signe Foghsgaard1,2,3, Louise Vedtofte1, Camilla Andreasen1, Emilie S Andersen1, Emilie Bahne1, Jonatan I Bagger1, Jens A Svare4, Jens J Holst2, Tine D Clausen5, Elisabeth R Mathiesen6, Peter Damm7, Filip K Knop1,2,8, Tina Vilsbøll9,10.   

Abstract

AIMS/HYPOTHESIS: We investigated whether a reduced incretin effect, as observed in patients with type 2 diabetes, can be detected in high-risk individuals, such as women with prior gestational diabetes mellitus (pGDM).
METHODS: In this cross-sectional study, 102 women without diabetes with pGDM and 15 control participants without pGDM and with normal glucose tolerance (NGT) underwent a 4 h 75 g OGTT and an isoglycaemic i.v. glucose infusion (IIGI). Women with pGDM were classified as having NGT or prediabetes (impaired fasting glucose and/or impaired glucose tolerance). Insulin sensitivity was assessed using the Matsuda index and HOMA2-IR and the incretin effect was calculated from insulin responses during the study (100% × [AUCinsulin,OGTT - AUCinsulin,IIGI]/AUCinsulin,OGTT).
RESULTS: Sixty-three of the 102 women with pGDM (62%) had prediabetes (median [interquartile range]: age, 38.3 [6.5] years; BMI, 32.1 [5.8] kg/m2) and 39 women (38%) had NGT (age, 39.5 [5.6] years; BMI, 31.0 [6.7] kg/m2). Control participants (n = 15) were not significantly different from the pGDM group with regards to age (39.2 [7.4] years) and BMI (28.8 [9.2] kg/m2). Compared with women with NGT and control participants, women with prediabetes had lower insulin sensitivity, as measured by the Matsuda index (3.0 [2.4] vs 5.0 [2.6] vs 1.5 [1.8], respectively; p < 0.001). The incretin effect was 55.3% [27.8], 73.8% [19.0] and 76.7% [24.6] in women with prediabetes, women with normal glucose tolerance and control participants, respectively (p < 0.01). CONCLUSION/
INTERPRETATION: Prediabetes was highly prevalent in women with pGDM, and alterations in the incretin effect were detected in this group before the development of type 2 diabetes. TRIAL REGISTRATION: clinicaltrialsregister.eu 2012-001371-37-DK.

Entities:  

Keywords:  Gestational diabetes mellitus; Impaired glucose tolerance; Incretin effect; Isoglycaemic i.v. glucose infusion; Oral glucose tolerance test; Prediabetes; Type 2 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28364253     DOI: 10.1007/s00125-017-4265-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  31 in total

Review 1.  Gestational diabetes after delivery. Short-term management and long-term risks.

Authors:  John L Kitzmiller; Leona Dang-Kilduff; M Mark Taslimi
Journal:  Diabetes Care       Date:  2007-07       Impact factor: 19.112

2.  Correct homeostasis model assessment (HOMA) evaluation uses the computer program.

Authors:  J C Levy; D R Matthews; M P Hermans
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

3.  Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

Authors:  J J Meier; B Gallwitz; M Askenas; K Vollmer; C F Deacon; J J Holst; W E Schmidt; M A Nauck
Journal:  Diabetologia       Date:  2005-07-12       Impact factor: 10.122

4.  Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus.

Authors:  M Kosinski; F K Knop; L Vedtofte; J Grycewiczv; P Swierzewska; K Cypryk; T Vilsbøll
Journal:  Regul Pept       Date:  2013-08-16

Review 5.  Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

Authors:  Steven E Kahn; Mark E Cooper; Stefano Del Prato
Journal:  Lancet       Date:  2013-12-03       Impact factor: 79.321

6.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

7.  Beta-cell dysfunction in first-degree relatives of patients with non-insulin-dependent diabetes mellitus.

Authors:  M Fernández-Castañer; J Biarnés; I Camps; J Ripollés; N Gómez; J Soler
Journal:  Diabet Med       Date:  1996-11       Impact factor: 4.359

8.  Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

Authors:  Filip K Knop; K Aaboe; T Vilsbøll; A Vølund; J J Holst; T Krarup; S Madsbad
Journal:  Diabetes Obes Metab       Date:  2012-01-17       Impact factor: 6.577

9.  Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals.

Authors:  Jonatan I Bagger; Filip K Knop; Asger Lund; Jens J Holst; Tina Vilsbøll
Journal:  Diabetologia       Date:  2014-05-31       Impact factor: 10.122

10.  Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.

Authors:  Kristine J Hare; Tina Vilsbøll; Jens J Holst; Filip K Knop
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-01-26       Impact factor: 4.310

View more
  1 in total

1.  Polysaccharide IV from Lycium barbarum L. Improves Lipid Profiles of Gestational Diabetes Mellitus of Pregnancy by Upregulating ABCA1 and Downregulating Sterol Regulatory Element-Binding Transcription 1 via miR-33.

Authors:  Shuli Yang; Lihui Si; Limei Fan; Wenwen Jian; Huilin Pei; Ruixin Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-23       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.